The announcement on the official website of the National Natural Science Foundation of China on April 11 also involved a case of academic misconduct related to a Chinese journal article.
On April 11, the official website of the National Natural Science Foundation of China notified the results of the first batch of 8 misconduct cases investigated and dealt with in 2023.
Due to suspected issues such as buying and selling experimental data, falsifying experimental data, marking fund projects without consent, using other people's signatures without consent, forging other people's email addresses, forging or tampering with pictures, and confusion in the use of pictures, the personnel involved in the aforementioned 8 cases were respectively revoked projects or Apply, recover the allocated funds, cancel the National Natural Science Foundation of China project application and participation qualifications for several years, and report criticism.
Of the 8 units involved in the aforementioned notification, 7 units are hospitals, medical schools, and medical universities, namely Guizhou Provincial People's Hospital, Qingdao Eighth People's Hospital, Jining Medical College, Gannan Medical College, Southern Medical University, and Central South University. (Cancer Hospital Affiliated to Xiangya School of Medicine, Central South University), Affiliated Hospital of Tianjin Academy of Traditional Chinese Medicine.
The aforementioned notification also involved a case of academic misconduct related to a Chinese journal article . The paper involves the Electric Power Research Institute of State Grid Beijing Electric Power Company (Beijing Electric Energy Meter Measurement and Verification Center). The paper "Fault Tolerant Redundancy Technology Monitoring Pumped Storage Power Station Electric Energy Measurement Error" published by Xian Huizhu and others of the center unauthorizedly marked other people's science fund projects.
Attached is the full text of the Notification of Handling Results of Misconduct Cases Investigated and Handled in 2023 (the first batch):
Recently, after the investigation and deliberation of the National Natural Science Foundation of China Supervision Committee and the approval of the National Natural Science Foundation of China Executive Meeting, the National Natural Science Foundation of China has dealt with the subjects involved in related scientific research misconduct cases. The relevant cases and handling results of the criticisms that have been notified are hereby notified.
(one)
The Supervision Committee of the National Natural Science Foundation of China launched an investigation into the suspected academic misconduct of 8 papers published by Fang Hua and Zhang Jianping of Guizhou Provincial People's Hospital. The papers involved are as follows:
Paper 1: Hua Fang#, Jianping Zhang* et al., Long non-coding RNA MALAT1 sponges microRNA-429 to regulate apoptosis of hippocampal neurons in hypoxic-ischemic brain damage by regulating WNT1. Brain Research Bulletin, 2019, 152, 1- 10.
Paper 2: Hua Fang#, Jianping Zhang* et al., MiR-132-3p modulates MEKK3-dependent NF-κB and p38/JNK signaling pathways to alleviate spinal cord ischemia-reperfusion injury by hindering M1 polarization of macrophages. Front. Cell . Dev. Biol. 2021, 9, 570451. (marked with fund numbers 81960239, 82060244)
Paper 3: Hua Fang#, Jianping Zhang* et al., Dexmedetomidine-up-regulated microRNA-381 exerts anti‐inflammatory effects in rats with cerebral ischaemic injury via the transcriptional factor IRF4. J. Cell. Mol. Med. 2021, 25 (4): 2098-2109. (Fund No. 81960239, 82060244)
Paper 4: Hua Fang#, Jianping Zhang* et al., Long noncoding RNA H19 overexpression protects against hypoxic-ischemic brain damage by inhibiting miR-107 and up-regulating vascular endothelial growth factor. Am. J. Pathol. 2021, 191( 3): 503-514. (marked with fund numbers 81960239, 82060244)
Paper 5: Hua Fang#, Jianping Zhang* et al., MicroRNA-128 enhances neuroprotective effects of dexmedetomidine on neonatal mice with hypoxic-ischemic brain damage by targeting WNT1. Biomed. Pharmacother. 2019, 113, 108671.
Paper 6: Jianping Zhang#, Hua Fang* et al., Propofol attenuates lung ischemia/reperfusion injury though the involvement of the MALAT1/microRNA-144/GSK3β axis. Molecular Medicine 2021, 27(1): 77. (marked fund number 81960239, 82060244)
Paper 7: Hua Fang#, Jianping Zhang* et al., MicroRNA-22-3p alleviates spinal cord ischemia/reperfusion injury by modulating M2 macrophage polarization via IRF5. J. Neurochem. 2021,156(1), 106-120 (marked Fund No. 81960239)
Paper 8: Hua Fang#, Jianping Zhang* et al., NF-κB signaling pathway inhibition suppresses hippocampal neuronal apoptosis and cognitive impairment via RCAN1 in neonatal rats with hypoxic-ischemic brain damage. Cell Cycle, 2019, 18-1, 108.1
After investigation, 8 involved papers had the problem of buying and selling experimental data, and the data in question were provided by third-party companies. The first author Fang Hua and the corresponding author Zhang Jian of papers 1, 2, 3, 4, 5, 7, and 8 Equality should be responsible for the problem of buying and selling experimental data in the above seven papers, and Zhang Jianping, the first author of paper 6, and Fang Hua, the corresponding author, should be responsible for the problem of buying and selling experimental data in this paper.
In addition, Fang Hua included papers 1, 3, 4, and 8 in the application for the fund project (approval number 82160251), paper 5 in the application for the fund project (approval number 81960239, 82160251), and paper 7 in the application for the fund project ( Approval No. 81960239) progress report; Zhang Jianping included papers 1, 5, and 8 in the application for the fund project (Approval No. 82060244), and the two should also be responsible for the objective results of false information in the project application or progress report.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Article 47, Item 2 of Article 42, and Article 46, revoke Fang Hua's National Natural Science Foundation of China project "Adipose stem cell exosomes transfer circRNA-0001107 to regulate inflammation Research on the Mechanism of Cell Phenotype Switching in Alleviating Spinal Cord Ischemia-Reperfusion Injury" (Approval No. 81960239), "Dexmedetomidine Mediates circRNA-0008446 Improves Neuronal Mitochondria After Ischemic Stroke Through m6A Methylation Modification Functional mechanism of dysfunction” (approval number 82160251), recover the allocated funds for the above two projects, cancel Fang Hua’s National Natural Science Foundation of China project application and participation qualification for 5 years (from February 6, 2023 to February 2028 5th), give a notice of criticism.
Decided to revoke Zhang Jianping's National Natural Science Foundation project " Adipose stem cell exosome lnc-Gm37494 regulates the phenotype transition of microglial cells and affects the mechanism of hypoxic-ischemic brain injury" (approval number 82060244), recovered the allocated funds, and canceled Zhang Jianping's National Natural Science Foundation of China project application and participation qualification For 5 years (from February 6, 2023 to February 5, 2028), a notice of criticism will be given.
(two)
National Natural Science Foundation of China Supervision Committee on the paper "Kuixiang Liu et al., Targeting survivin suppresses proliferation and invasion of retinoblastoma cells in vitro and in vivo. International Journal of Clinical and Experimental Pathology, 2017" published by Liu Kuixiang, Qingdao Eighth People's Hospital, etc. , 10(9): 9352." (marked fund number 81170825) was investigated for alleged academic misconduct.
After investigation, the papers involved had problems such as falsifying experimental data, marking fund projects without authorization, using other people's signatures without consent, and forging other people's email addresses. The first author Liu Kuixiang should be responsible for the above problems.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Article 47, Article 40, and Item 1 and Item 6 of Article 43 cancel Liu Kuixiang's qualification to apply for and participate in the National Natural Science Foundation of China for 4 years (2023 February From February 6 to February 5, 2027), a circular of criticism will be given.
(three)
The Supervision Committee of the National Natural Science Foundation of China reviewed the paper "Pengmu Xie et al., Knockdown of lncRNA CCAT2 inhibits endometrial cancer cells growth and metastasis via sponging miR-216b. Cancer Biomarkers, 2018, 21(1): 123-133." An investigation was launched for alleged academic misconduct.
After investigation, the paper involved had problems such as fabricating the research process, forging the email address of the corresponding author, and using other people's signatures without consent. The first author Xie Pengmu should be responsible for the above problems.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jinfacheng [2020] No. 96) Article 40 and Article 43, Item 1, cancel Xie Pengmu's National Natural Science Foundation of China project application and participation qualification for 4 years (from February 6, 2023 to February 5, 2027 ), giving a notification of criticism.
(Four)
The Supervision Committee of the National Natural Science Foundation of China launched an investigation into the three papers published by Wu Longhuo and Cheng Qilai of Gannan Medical College for suspected academic misconduct. The papers involved are as follows:
Paper 1: Longhuo Wu* et al., TMF protects chondrocytes from ER stress-induced apoptosis by down-regulating GSK-3β. Biomedicine & Pharmacotherapy, 2017, 89, 1262-1268. (Fund No. 81360277, 81660371)
Paper 2: Qilai Cheng#, Longhuo Wu* et al., Asiatic acid (AA) sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin (DDP) via downregulation of P-glycoprotein (MDR1) and its targets. Cellular Physiology and Biochemistry, 2018, 47, 279-292. (Fund No. 81360627, 81660371)
Paper 3: Longhuo Wu* et al., TMF inhibits miR-29a/Wnt/β-catenin signaling through upregulating Foxo3a activity in osteoarthritis chondrocytes. Drug Design, Development and Therapy, 2019, 13, 2009-2019. (Fund No. 8166037 , 81860388, 81860261)
After investigation, it was found that the three involved papers had forged and tampered with the experimental pictures. Wu Longhuo, the corresponding author of Paper 1 and Paper 3, and Cheng Qilai, the first author of Paper 2, and Wu Longhuo, the corresponding author of Paper 2, should be responsible for the above problems.
In addition, Wu Longhuo included Paper 1 in the application for the Fund Project (Approval No. 82060407) and the conclusion report of the Fund Project (Approval No. No. 81660371) progress report and final report, and should also be responsible for the objective results of false information in the project application/progress report/conclusion report.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Articles 47, 46, and 40, canceling the Wu Longhuo National Natural Science Foundation of China project "Study on the Mechanism of Endoplasmic Reticulum Stress-Induced Chondrocyte Apoptosis Based on GSK-3β and the intervention effect of jiulixiang” (approval number 81360277), “the molecular mechanism of miR-29a regulating Wnt/β-catenin signaling in osteoarthritis chondrocytes and the intervention effect of jiulixiangone” (approval number 81660371) and “TMF Inhibit osteoarthritis chondrocyte apoptosis by activating the FOXO3a/SOCS3 signaling pathway" (approval number 82060407), recover the allocated funds for the above three projects, and cancel Wu Longhuo's National Natural Science Foundation of China project application and participation qualification for 3 years (2023 From February 6, 2026 to February 5, 2026), a circular of criticism will be given.
Decided to revoke Cheng Qilai's National Natural Science Foundation of China project "Based on NF-κB Research on the anti-tumor active ingredients of ursane-type triterpenoids in Gannan Chinese herbal medicine" (approval number 81360627), recover the allocated funds, and cancel Cheng Qilai's National Natural Science Foundation of China project application and participation qualification for 3 years (from February 6, 2023 to February 5, 2026), a circular of criticism was given.
(five)
The Supervision Committee of the National Natural Science Foundation of China reviewed the paper "Yadong Zhang#* et al., Cx43- and Smad-Mediated TGF-β/BMP Signaling Pathway Promotes Cartilage Differentiation of Bone Marrow Mesenchymal Stem Cells and Inhibits Osteoblast Differentiation. Cellular Physiology and Biochemistry, 2017, 42(4): 1277-1293." (marked fund number 51672191, 81601886) was investigated for alleged academic misconduct.
After investigation, there were problems of forgery and tampering of pictures in the papers involved. The first author and corresponding author Zhang Yadong and others were responsible for the above problems.
In addition, Zhang Yadong included the paper involved in the application for the fund project (approval number 81871774) and the progress report of the fund project (approval number 51672191), and he should also be responsible for the objective results of false information in the project application or progress report.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Articles 47, 40, and 46, revoking Zhang Yadong's National Natural Science Foundation of China project "Three-dimensional printing of hypoxic simulated borate bioglass scaffolds to activate HIF-1α pathway therapy Steroid-induced necrosis of the femoral head" (approval number 51672191) and "Three-dimensional printed borate bioglass scaffold loaded with MSCs-derived exosomes to activate Wnt/β-catenin signaling pathway in the treatment of large bone defects" (approval number 81871774), recover the above For the allocated funds of the 2 projects, Zhang Yadong’s National Natural Science Foundation of China project application and participation qualifications will be canceled for 3 years (from February 6, 2023 to February 5, 2026), and criticism will be issued.
(six)
The Supervision Committee of the National Natural Science Foundation of China launched an investigation into the suspected academic misconduct of two papers published by Tang Faqing of Central South University (successively worked in Jinan University and Central South University). The involved papers are as follows:
Paper 1: Faqing Tang* et al., MICAL2 mediates p53 ubiquitin degradation through oxidating p53 methionine 40 and 160 and promotes colorectal cancer malignance. Theranostics, 2018, 8(19): 5289-5306. (Fund No. 81402268, 814 , 81372282, 81502346)
Paper 2: Faqing Tang* et al., Dinitrosopiperazine-mediated phosphorylated-proteins are involved in nasopharyngeal carcinoma metastasis. Int. J. Mol. Sci., 2014, 15(11): 20054-20071. (Fund No. 81071718, 8100081 , 81402368, 81402265)
After investigation, the two involved papers had the problem of confusion in the use of pictures, and Tang Faqing, the corresponding author of Paper 1 and Paper 2, should be responsible for the above problems.
In addition, Tang Faqing included paper 1 in the progress report of the fund project (approval number 81872226), and paper 2 in the application form of the fund project (approval number 81872226), and also dealt with the objective results of false information in the fund project application or progress report Responsible.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Article 47, Article 46, and Article 40, revoke Tang Faqing's National Natural Science Foundation of China project "Chemical carcinogen DNP-activated super-enhancer regulates MICAL2 to promote the metastasis of nasopharyngeal carcinoma Mechanism Research" (approval number 81872226), recover the allocated funds, disqualify Tang Faqing from applying for and participating in the National Natural Science Foundation of China for 3 years (from February 6, 2023 to February 5, 2026), and give a notice of criticism.
(seven)
The Supervision Committee of the National Natural Science Foundation of China launched an investigation into Jiang Lujian, a hospital affiliated to the Tianjin Academy of Traditional Chinese Medicine, for alleged academic misconduct.
After investigation, Jiang Lujian copied the project application from someone else's computer without permission, and used the content of the application to apply for the National Natural Science Foundation of China project "Research on Xiaoyao Powder Regulating miR-145/AMPK/mTOR Pathway Inhibiting Autophagy and Reversing Drug Resistance in Breast Cancer Cells" ( Application No. 8220154428), there is a problem of plagiarizing the content of other people's applications, and Jiang Lujian should be responsible for the above problems.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jin Facheng [2020] No. 96) Article 40, revoked Jiang Lujian's National Natural Science Foundation of China project "Xiaoyao powder regulates miR-145/AMPK/mTOR pathway to inhibit autophagy and reverse drug resistance of breast cancer cells" (application number 8220154428), Cancel Jiang Lujian's National Natural Science Foundation of China project application and participation qualification for 3 years (from February 6, 2023 to February 5, 2026), and give a notice of criticism.
(eight)
The Supervision Committee of National Natural Science Foundation of China issued a paper "Xianhuizhu* et al. Monitoring Pumped Storage Power Station with Fault Tolerant Redundancy Technology" published by Xianhuizhu et al. Electric energy measurement error. Water Conservancy and Hydropower Technology, 2020, 51(10): 96-103." (marked with fund number 51709125) was investigated for alleged academic misconduct.
After investigation, according to the results of the magazine's assisted investigation and the evidence provided, the paper involved had the problem of labeling other people's science fund projects without authorization, and the first author and corresponding author Xian Huizhu should be responsible for the above problems. In addition, Xianhuizhu is also responsible for the issue of providing false statements during the investigation.
After deliberation at the 16th meeting of the 5th Supervision Committee of the National Natural Science Foundation of China and the approval of the 2nd executive meeting of the National Natural Science Foundation of China in 2023, it was decided to follow the "Measures for Investigation and Handling of Misconduct in Scientific Research of National Natural Science Foundation of China Projects" (National Science Foundation of China) Jinfacheng [2020] No. 96) Article 48, Article 47, and Item 6 of Article 43 cancel the application and participation qualifications for the Xianhuizhu National Natural Science Foundation of China for 3 years (February 2023 6 to February 5, 2026), and give a circular of criticism.
